Recent Performance Snapshot for Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals (ARWR) has drawn attention after recent share price moves, with the stock closing at $78.89 and showing mixed short term returns, including a slight decline over the past week and a small gain over the past month.

Looking past the latest pullback, Arrowhead Pharmaceuticals has had a strong run, with the 90 day share price return of 36.84% alongside a very large 1 year total shareholder return of 390.61%, which suggests momentum has been building rather than fading.

If recent moves in Arrowhead Pharmaceuticals have you thinking about similar opportunities in healthcare, it could be a good time to scan for other potential ideas using our 39 healthcare AI stocks

With Arrowhead Pharmaceuticals trading at $78.89, alongside a large intrinsic discount estimate of 54.97% and a modest 12.92% gap to the current analyst price target, you have to ask: is there still a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 28.3% Undervalued

On the most followed narrative, Arrowhead Pharmaceuticals is framed with a fair value of $110 per share against the latest close at $78.89, putting a spotlight on what assumptions are needed for that gap to make sense.

The company's capability to regularly advance 3 to 4 new wholly-owned drug candidates into the clinic every year, backed by a now-proven, modular multi-organ RNAi delivery platform, gives Arrowhead a unique capacity to continuously expand and diversify its pipeline, laying the foundation for compounding, multi-product revenue streams that substantially amplify long-term earnings power and valuation.

Curious what kind of revenue ramp and margin profile sit behind that $110 fair value for Arrowhead Pharmaceuticals, and how the discount rate and future earnings projections all fit together in this narrative? The full story connects ambitious growth forecasts, a shift from losses to profits, and a valuation multiple more often seen in fast growing sectors.

Result: Fair Value of $110.0 (UNDERVALUED)

However, this Arrowhead Pharmaceuticals narrative can unwind quickly if costly late stage trials disappoint, or if heavy cash burn forces fresh capital raises that dilute shareholders.

Another View on Arrowhead Pharmaceuticals Valuation

The bullish narrative leans heavily on future earnings and a fair value of $110 per share, yet our SWS DCF model already suggests Arrowhead Pharmaceuticals is trading at a very large discount, with the stock at $78.89 compared with an estimated future cash flow value of $175.19. That raises a simple question: which set of assumptions do you trust more?

Next Steps

Mixed signals around Arrowhead Pharmaceuticals so far, right? If you want to move quickly and shape your own view, consider both perspectives by checking the 2 key rewards and 1 important warning sign

Looking for more investment ideas beyond Arrowhead Pharmaceuticals?

If Arrowhead Pharmaceuticals has sharpened your focus, do not stop here. Broaden your watchlist with other clear, data driven ideas that could suit your style.

• Target resilient companies with healthy fundamentals by scanning our solid balance sheet and fundamentals stocks screener (48 results) and see which stocks stand out on balance sheet strength.
• Hunt for potential value opportunities using the 44 high quality undervalued stocks and spot stocks where current prices differ meaningfully from their fundamentals.
• Aim for quality that the market may be overlooking by checking the screener containing 19 high quality undiscovered gems before these stocks land on everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.